Skye Bioscience, Inc.
OTC:SKYE
4.12 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | Skye Bioscience, Inc. |
| Symbool | SKYE |
| Munteenheid | USD |
| Prijs | 4.12 |
| Beurswaarde | 127,672,208 |
| Dividendpercentage | 0% |
| 52-weken bereik | 1.14 - 7.11 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Punit S. Dhillon B.A., BA |
| Website | https://skyebioscience.com |
An error occurred while fetching data.
Over Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)



